Clinical Trial Update: Post-Marketing Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Ipragliflozin in Combination With GLP-1 Receptor Agonists in Japanese Patients With Type 2 Diabetes Mellitus (T2DM) [Phase 4]

View source ↗

Summary

Phase 4 post-marketing study evaluating the long-term safety, tolerability, and efficacy of ipragliflozin in combination with GLP-1 receptor agonists in Japanes…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• ipragliflozin (ipragliflozin)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Type 2 Diabetes Mellitus | Phase 4 | Status: COMPLETED